This demo IO360 report presents simulated data to represent a cohort of 144 colorectal cancers biopsies from 48 patients that have been treated with an immune checkpoint inhibitor. In this mock cohort, the samples have been enriched to be 50% microsatellite instable (MSI) tumors (which have higher DNA mutation rate and enhanced propensity to respond to immunotherapy) and 50% microsatellite stable (MSS) tumors (low mutation rate and lower response rate to IO). In this cohort, mutational status was determined by the conventional MSI qPCR assay and provided to NanoString as a sample annotation. Samples were collected as serial biopsies of a single lesion per patient during a clinical trial for a novel IO agent at 3 timepoints: prior to start of treatment, at 3 weeks into the study, and at 6 weeks into the study.
 For profiling with the human PanCancer IO 360 panel, RNA was purified from FFPE tissue sections and 100 ng was used in the hybridization. 
IO360 data was analyzed with the IO360 report. 
